Drugs
Gilead Abandons Jyseleca for RA in the U.S.
Gilead Sciences and Galapagos are scrapping the U.S. development of Jyseleca (filgotinib) for Rheumatoid Arthritis (RA) after a recent meeting with FDA to discuss an 8/18 NDA complete response letter over testicular toxicity concerns. FDA told the companies that “substantial additional clinical studies” would be required to support